摘要:
Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R5 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.
摘要翻译:公开了式1化合物,其中V是CH 2; W为S(O)m; m是整数0,1或2; U是O,C(O),CR 13 R 14或NR 15; 其中R 13为H,烷基; R14是H,OH,OR13或OCOR13; R 15是H,烷基,环烷基,烯基,C(O)R 13,C(O)OR 13或烷基氨基羰基; R1,R2,R3,R4,R5,R6,R7和R5如本文所定义。 这些化合物是肿瘤坏死因子-α(TNF-α)的抑制剂,可用作治疗和预防由增加的TNF-α活性引起的疾病,特别是炎症的药物。
摘要:
Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.
摘要翻译:公开了式1的化合物,其中V是CH 2 2; W是S(O)m。 m是整数0,1或2; U是O,C(O),CR 13 R 14或NR 15; 其中R 13是H,烷基; R 14是H,OH,OR 13或OCOR 13; R 15是H,烷基,环烷基,烯基,C(O)R 13,C(O)OR 13或烷基氨基羰基; R 1,R 2,R 3,R 4,R 5, R 6,R 7和R 8是如本文所定义的。 这些化合物是肿瘤坏死因子-α(TNF-α)的抑制剂,可用作治疗和预防由增加的TNF-α活性引起的疾病,特别是炎症的药物。
摘要:
Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.
摘要翻译:公开了式1化合物,其中V是CH 2; W为S(O)m; m是整数0,1或2; U是O,C(O),CR 13 R 14或NR 15; 其中R 13为H,烷基; R14是H,OH,OR13或OCOR13; R 15是H,烷基,环烷基,烯基,C(O)R 13,C(O)OR 13或烷基氨基羰基; R1,R2,R3,R4,R5,R6,R7和R8如本文所定义。 这些化合物是肿瘤坏死因子-α(TNF-α)的抑制剂,可用作治疗和预防由增加的TNF-α活性引起的疾病,特别是炎症的药物。
摘要:
Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.
摘要翻译:公开了式1化合物,其中V是CH 2; W为S(O)m; m是整数0,1或2; U是O,C(O),CR 13 R 14或NR 15; 其中R 13为H,烷基; R14是H,OH,OR13或OCOR13; R 15是H,烷基,环烷基,烯基,C(O)R 13,C(O)OR 13或烷基氨基羰基; R1,R2,R3,R4,R5,R6,R7和R8如本文所定义。 这些化合物是肿瘤坏死因子-α(TNF-α)的抑制剂,可用作治疗和预防由增加的TNF-α活性引起的疾病,特别是炎症的药物。
摘要:
The present invention relates to a process for the preparation of the compounds of formula (I) which are morpholino sulphonyl indole derivatives. The compounds of formula (I) are capable of inhibiting, modulating or regulating Insulin-Like-Growth Factor I Receptors or Insulin Receptors. The present invention also relates to the processes for preparation of the pharmaceutically acceptable salts of the compounds of formula (I).